[go: up one dir, main page]

WO2001015664A3 - Procedes de coformulation et leurs produits - Google Patents

Procedes de coformulation et leurs produits Download PDF

Info

Publication number
WO2001015664A3
WO2001015664A3 PCT/GB2000/003328 GB0003328W WO0115664A3 WO 2001015664 A3 WO2001015664 A3 WO 2001015664A3 GB 0003328 W GB0003328 W GB 0003328W WO 0115664 A3 WO0115664 A3 WO 0115664A3
Authority
WO
WIPO (PCT)
Prior art keywords
coformulation
active
products
methods
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2000/003328
Other languages
English (en)
Other versions
WO2001015664A2 (fr
Inventor
Peter York
Simon Anthony Wilkins
Richard Anthony Storey
Stephen Ernest Walker
Ronald Scott Harland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics UK Ltd
Bristol Myers Squibb Co
Original Assignee
Bradford Particle Design Ltd
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bradford Particle Design Ltd, Bristol Myers Squibb Co filed Critical Bradford Particle Design Ltd
Priority to EP00956682A priority Critical patent/EP1207856A2/fr
Priority to MXPA02001803A priority patent/MXPA02001803A/es
Priority to KR1020027002715A priority patent/KR20020047137A/ko
Priority to CA002382556A priority patent/CA2382556A1/fr
Priority to JP2001519878A priority patent/JP2003508419A/ja
Priority to AU68550/00A priority patent/AU783570B2/en
Publication of WO2001015664A2 publication Critical patent/WO2001015664A2/fr
Publication of WO2001015664A3 publication Critical patent/WO2001015664A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0407—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solute
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0488—Flow sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une coformulation d'une substance active (de préférence active au plan pharmaceutique, comme par exemple un inhibiteur enzymatique COX-2) et d'un excipient oligomère ou polymère, contenant au moins 10 % de substance active dont 80 à 100 % est actif. La phase amorphe est stable, par rapport à la/aux phases cristallines, pendant au moins trois mois après sa préparation, lorsqu'elle est stockée entre 0 et 10 °C. L'invention porte également sur des procédés, impliquant de préférence la formation de particules SEDSTM, pour la préparation de ladite coformulation.
PCT/GB2000/003328 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits Ceased WO2001015664A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP00956682A EP1207856A2 (fr) 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits
MXPA02001803A MXPA02001803A (es) 1999-08-31 2000-08-31 Metodos de coformulacion y sus productos.
KR1020027002715A KR20020047137A (ko) 1999-08-31 2000-08-31 공조제 방법 및 그것의 산물
CA002382556A CA2382556A1 (fr) 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits
JP2001519878A JP2003508419A (ja) 1999-08-31 2000-08-31 共配合方法およびそれらの製品
AU68550/00A AU783570B2 (en) 1999-08-31 2000-08-31 Coformulation methods and their products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9920558.5 1999-08-31
GBGB9920558.5A GB9920558D0 (en) 1999-08-31 1999-08-31 Methods for particle formation and their products

Publications (2)

Publication Number Publication Date
WO2001015664A2 WO2001015664A2 (fr) 2001-03-08
WO2001015664A3 true WO2001015664A3 (fr) 2001-09-20

Family

ID=10860085

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003328 Ceased WO2001015664A2 (fr) 1999-08-31 2000-08-31 Procedes de coformulation et leurs produits

Country Status (8)

Country Link
EP (1) EP1207856A2 (fr)
JP (1) JP2003508419A (fr)
KR (1) KR20020047137A (fr)
AU (1) AU783570B2 (fr)
CA (1) CA2382556A1 (fr)
GB (2) GB9920558D0 (fr)
MX (1) MXPA02001803A (fr)
WO (1) WO2001015664A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US9120031B2 (en) 2000-11-09 2015-09-01 Nektar Therapeutics Compositions of particulate coformulation
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038162T2 (de) 1999-12-08 2009-02-26 Pharmacia Corp. Celecoxib in festkörperform mit erhöhter bioverfügbarkeit
CH694686A5 (it) 2000-03-04 2005-06-15 Eco2 Sa Prodotto di micronizzazione di sostanze farmaceutiche.
FR2815540B1 (fr) † 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
GB0102075D0 (en) 2001-01-26 2001-03-14 Astrazeneca Ab Process
BR0210000A (pt) * 2001-05-30 2004-05-04 Csir Método de encapsular uma substância ativa
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US20050260273A1 (en) * 2001-06-07 2005-11-24 Chinea Vanessa I Applicatin of a bioactive agent in a solvent composition to produce a target particle morphology
WO2003000235A1 (fr) 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
CA2464308A1 (fr) 2001-10-22 2003-05-01 Dompe S.P.A. Traitement de fluides supercritiques : preparation de microparticules de proteines et leur stabilisation
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
AU2004237131B2 (en) 2003-05-08 2009-09-10 Nektar Therapeutics Particulate materials
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
EP2476412B1 (fr) 2006-10-11 2014-03-19 Crititech, Inc. Appareil de précipitation de petites particules de médicaments dans des conteneurs d'utilisation
GB0702402D0 (en) * 2007-02-08 2007-03-21 Thar Pharmaceuticals Inc Method of creating crystalline substances
WO2009072950A1 (fr) 2007-12-07 2009-06-11 Xspray Microparticles Ab Procédé et dispositif pour la production de particules
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
CA2767773C (fr) 2011-02-11 2015-11-24 Grain Processing Corporation Composition comprenant un sel et un agent d'interruption de cristallisation
FI3181128T3 (fi) * 2012-01-13 2023-06-02 Xspray Pharma Ab Publ Nilotinibin farmaseuttinen koostumus
HRP20210237T1 (hr) * 2012-01-13 2021-03-19 Xspray Microparticles Ab Postupak za proizvodnju stabilnih, amorfnih hibridnih nanočestica koje sadrže barem jedan inhibitor proteinske kinaze i barem jedan polimerni sastojak koji stabilizira i tvori matricu

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404183A (en) * 1979-07-05 1983-09-13 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
WO1992011000A1 (fr) * 1990-12-22 1992-07-09 Schwarz Pharma Ag Procede pour la fabrication de microparticules constituees de polymeres hydrolytiquement degradables et contenant des principes actifs
EP0582169A2 (fr) * 1992-08-05 1994-02-09 Bayer S.p.A. Préparations pharmaceutiques pour l'administration orale des dihydropyridines sous forme de boisson
WO1995001221A1 (fr) * 1993-07-01 1995-01-12 University Of Bradford Procede et appareillage permettant la formation de particules
WO1996031202A1 (fr) * 1995-04-03 1996-10-10 Elan Corporation, Plc Microspheres et nanospheres biodegradables a liberation lente renfermant de la cyclosporine
WO1997031691A1 (fr) * 1996-03-01 1997-09-04 The University Of Kansas Procedes et appareil pour la precipitation et l'enrobage de particules au moyen d'antisolvants quasi-critiques et supercritiques
WO1997044028A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2
WO1998013136A1 (fr) * 1996-09-25 1998-04-02 Mainelab Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
EP0852140A1 (fr) * 1995-08-11 1998-07-08 Nissan Chemical Industries, Limited Procedes permettant de rendre amorphes des medicaments peu solubles
WO1999025322A2 (fr) * 1997-11-19 1999-05-27 Eurand International S.P.A. Compositions pharmaceutiques ayant la forme de poudres de polymeres reticules charges de medicaments et procede de preparation correspondant au moyen de fluides supercritiques
WO2001003821A1 (fr) * 1999-07-07 2001-01-18 Bradford Particle Design Limited Procede de formation de particules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462066A1 (fr) * 1990-06-15 1991-12-18 Warner-Lambert Company Gemfibrozil amorphe
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404183A (en) * 1979-07-05 1983-09-13 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical composition of solid medical material
WO1992011000A1 (fr) * 1990-12-22 1992-07-09 Schwarz Pharma Ag Procede pour la fabrication de microparticules constituees de polymeres hydrolytiquement degradables et contenant des principes actifs
EP0582169A2 (fr) * 1992-08-05 1994-02-09 Bayer S.p.A. Préparations pharmaceutiques pour l'administration orale des dihydropyridines sous forme de boisson
WO1995001221A1 (fr) * 1993-07-01 1995-01-12 University Of Bradford Procede et appareillage permettant la formation de particules
WO1996031202A1 (fr) * 1995-04-03 1996-10-10 Elan Corporation, Plc Microspheres et nanospheres biodegradables a liberation lente renfermant de la cyclosporine
EP0852140A1 (fr) * 1995-08-11 1998-07-08 Nissan Chemical Industries, Limited Procedes permettant de rendre amorphes des medicaments peu solubles
WO1997031691A1 (fr) * 1996-03-01 1997-09-04 The University Of Kansas Procedes et appareil pour la precipitation et l'enrobage de particules au moyen d'antisolvants quasi-critiques et supercritiques
WO1997044028A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions pour traitement journalier monodose de maladies a mediateur cyclooxygenase-2
WO1998013136A1 (fr) * 1996-09-25 1998-04-02 Mainelab Procede de preparation de microcapsules de matieres actives enrobees par un polymere et nouvelles microcapsules notamment obtenues selon le procede
WO1999025322A2 (fr) * 1997-11-19 1999-05-27 Eurand International S.P.A. Compositions pharmaceutiques ayant la forme de poudres de polymeres reticules charges de medicaments et procede de preparation correspondant au moyen de fluides supercritiques
WO2001003821A1 (fr) * 1999-07-07 2001-01-18 Bradford Particle Design Limited Procede de formation de particules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEBENEDETTI P G ET AL: "APPLICATION OF SUPERCRITICAL FLUIDS FOR THE PRODUCTION OF SUSTAINED DELIVERY DEVICES", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 24, no. 1 / 03, 1 May 1993 (1993-05-01), pages 27 - 44, XP000303918, ISSN: 0168-3659 *
SHEKUNOV B. ET AL: "Control of Particle Morphology using solution enhanced dispersion by supercritical fluids (SEDS)", PHARM. RES., vol. 14, 1997, pages 195 - 196, XP000905093 *
TAYLOR L. ET AL: "Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions", PHARM. RES., vol. 14, 1997, pages 1691 - 1698, XP000905065 *
WILKINS S. ET AL: "The formation of indomethacin:polymer co-precipitates by the solution enhanced dispersion by supercritical fluids (SEDS) process", J. OF PHARMACY AND PHARMACOLOGY, vol. 51, September 1999 (1999-09-01), pages 291, XP000905174 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US9120031B2 (en) 2000-11-09 2015-09-01 Nektar Therapeutics Compositions of particulate coformulation
US8936813B2 (en) 2001-11-01 2015-01-20 Novartis Ag Spray drying methods and related compositions
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile

Also Published As

Publication number Publication date
MXPA02001803A (es) 2004-02-26
EP1207856A2 (fr) 2002-05-29
KR20020047137A (ko) 2002-06-21
AU783570B2 (en) 2005-11-10
GB2355194A (en) 2001-04-18
GB9920558D0 (en) 1999-11-03
WO2001015664A2 (fr) 2001-03-08
AU6855000A (en) 2001-03-26
GB0021227D0 (en) 2000-10-18
GB2355194B (en) 2003-01-08
JP2003508419A (ja) 2003-03-04
CA2382556A1 (fr) 2001-03-08

Similar Documents

Publication Publication Date Title
WO2001015664A3 (fr) Procedes de coformulation et leurs produits
AU2001278771A1 (en) Carboxylic acid derivatives, process for producing the same and drugs containingthe same as the active ingredient
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
AU2001262723A1 (en) 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
EP1728791A4 (fr) Composition pour la preparation pharmaceutique solide de solifenacine ou des sels de cette derniere
AU5194999A (en) Benzothiepin derivatives, process for the preparation of the same and uses thereof
AU7962200A (en) Novel indole derivatives and drugs containing the same as the active ingredient
AU7079700A (en) Improved stable formulations of ace inhibitors, and methods for preparation thereof
WO1995009619A3 (fr) Derives substitues de l'uree et de l'isothiouree utilises comme inhibiteurs de l'oxyde nitrique synthase
WO2001008688A3 (fr) PRODUITS DE MEDICAMENTS A BASE DE β-CARBOLINE
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
AU5647199A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU5426500A (en) Benzazepine derivatives, process for the preparation of the same and uses thereof
CA2238389A1 (fr) Nouveaux derives geranyl-geranyle, procede pour les preparer et compositions pharmaceutiques les contenant
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU2466700A (en) Process for the preparation of urea
AU7972200A (en) Process for the preparation of urea
AU3669700A (en) 4-aminobutanoic acid derivatives and drugs containing these derivatives as the active ingredient
CA2292629A1 (fr) Composition renfermant de la 5-¬4-¬2-(n-methyl-n-2-pyridyl)amino)ethoxy|benzyl|thiazolidine-2,4-dione
AU5820900A (en) Capsule for the controlled release of active substances
AU5443499A (en) Carboxylic acid derivatives and drugs containing the same as the active ingredient
AU6314200A (en) Carboxylic acid derivatives and adhesion molecule inhibitors containing the sameas the active ingredient
AU2002325614A1 (en) Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances
HUP0203212A3 (en) Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions
CA2352430A1 (fr) Nouvelle composition pharmaceutique et procede de preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/207/KOL

Country of ref document: IN

Ref document number: 68550/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001803

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2001 519878

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2382556

Country of ref document: CA

Ref document number: 1020027002715

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000956682

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000956682

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027002715

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 68550/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000956682

Country of ref document: EP